Acer Medical, a subsidiary of Acer Group specializing in medical imaging and AI-powered healthcare solutions, showcased its new aiMed platform at the global next@acer event during IFA. Designed specifically for clinical environments, aiMed can instantly convert spoken or written input from healthcare professionals into structured medical records. This milestone underscores Acer Medical’s commitment to driving healthcare transformation through AI and digital innovation, and marks a key step in its strategy to expand globally.

Acer highlighted that aiMed addresses one of the most pressing challenges in modern healthcare—administrative overload from medical documentation. Healthcare professionals currently spend as much as 25% of their daily work hours on recordkeeping, cutting into patient care time and contributing to burnout.

aiMed leverages real-time AI processing tailored to clinical settings, built with medical terminology and contextual understanding, and operates on a secure cloud infrastructure to protect data. It can convert speech or text into structured electronic medical records (EMRs) while ensuring accuracy, completeness, and compliance with complex healthcare documentation standards, greatly streamlining clinical workflows.

By automating this task, aiMed helps reduce healthcare professionals’ administrative burden, lower documentation errors, maintain interoperability with hospital information systems (HIS/EMR platforms), and enhance patient safety and quality of care—freeing doctors and nurses to spend more time on patient treatment.

Acer Medical also introduced its AI-assisted ophthalmology analysis platform, VeriSee, which integrates existing and newly developed AI modules to support diverse clinical needs. The platform currently includes: VeriSee DR for diabetic retinopathy screening, VeriSee AMD for age-related macular degeneration screening, and VeriSee GLC for suspected glaucoma screening.

VeriSee can analyze for all three conditions within seconds, enabling hospitals and clinics to efficiently identify high-risk patients and provide timely intervention to improve preventive care outcomes. The AI-based screening tool has already been deployed in 14 markets worldwide, with an estimated 500 clinics and hospitals using the system.

Previously focused mainly on Asian markets—especially Taiwan and Southeast Asia—this marks Acer Medical’s first product launch at IFA in Europe, signaling the company’s international expansion beyond Asia into Europe and North America.

Resource: 宏碁衝刺醫療保健AI商機 旗下宏碁智醫於IFA發表aiMed